A multicenter retrospective study discussion on maintenance treatment strategies for mantle cell lymphoma
10.3760/cma.j.cn121090-20240118-00032
- VernacularTitle:套细胞淋巴瘤患者维持治疗方案的多中心回顾性研究
- Author:
Ping YANG
1
;
Lan LUO
;
Shuozi LIU
;
Chunyuan LI
;
Yingtong CHEN
;
Wei ZHANG
;
Hui LIU
;
Xiubin XIAO
;
Hongmei JING
Author Information
1. 北京大学第三医院，北京 100191
- Keywords:
Lymphoma, mantle cell;
Real-world study;
Maintenance treatment strategies
- From:
Chinese Journal of Hematology
2024;45(7):660-665
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aims to explore the survival advantages of different maintenance strategies for MCL.Methods:Clinical data of 693 newly diagnosed MCL patients in multi-centers admitted from April 1999 to December 2019 were collected. 309 cases received maintenance treatment. The characteristics of patients in different maintenance treatment groups were summarized and Kaplan-Meier survival and prognosis analysis were conducted.Results:The overall 3-year and 5-year progression-free survival (PFS) rates were (73.5±2.9) % and (53.6±4.3) %, respectively. The 3-year and 5-year overall survival (OS) rates were (94.2±1.5) % and (82.7±3.2) %, respectively. The clinical features of different maintenance treatment groups were generally consistent. The 3-year PFS rates of rituximab maintenance, lenalidomide maintenance, BTK inhibitor maintenance and dual-drug maintenance were (70.4±4.1) %, (69.1±7.6) %, (86.9±5.0) %, and (80.4±5.1) %, respectively. Corresponding 3-year OS rates were (92.9±2.4) %, (97.3±2.7) %, (97.9±2.1) %, and (95.3±2.7) %, respectively. There were no significant difference in different groups ( P=0.632, 0.313). Survival analysis identified the MCL International Prognostic Index (MIPI) high-risk group and achieving complete remission before maintenance treatment as independent risk factors for PFS. The MIPI high-risk group, high-dose cytarabine application, treatment lines, and early disease progression (POD24) emerged as independent risk factors for OS. Conclusion:Comparing the different maintenance strategies of MCL, the result showed that BTK inhibitors (BTKi) maintenance demonstrated preliminary advantages in survival. Meanwhile, high-risk group according to MIPI and incomplete remission before maintenance treatment were significant factors related to disease progression.
